Our latest article is part Journal Club entry for August, part look back at some data from AACR and ASCO plus a part look at a relatively new target from an obscure biotech that caught my attention recently.
To do this, we pose three critical questions and attempt to answer them.
The targets and markers chosen for review here may well surprise a few people.
If we want to understand how to help more people respond to cancer immunotherapy then we need o understand the underlying biology and the tumour microenvironment in greater depth than we currently do.
Gradually, we are getting more clarity on a few areas as new data is being published…